• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

807640-87-5 (BGB-102)

1

Identification

BGB-102 BGB-102
Name BGB-102
Formula C22H25BrN4O2
MW 457.36
CAS No. 807640-87-5
EINECS
Smiles CN1CCCCCOC(C(OC)=C2)=CC3=C2N=CN/C3=NC4=CC(Br)=CC=C4C1
Synonyms JNJ-26483327;BGB102;BGB 102;JNJ26483327;JNJ 26483327;
InChI InChI=1S/C22H25BrN4O2/c1-27-8-4-3-5-9-29-21-11-17-19(12-20(21)28-2)24-14-25-22(17)26-18-10-16(23)7-6-15(18)13-27/h6-7,10-12,14H,3-5,8-9,13H2,1-2H3,(H,24,25,26)
2

Introduction

BGB-102 is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively.

Background Information

JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal ......by BOC Sciences
BGB-102 is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. ......by MedChemexpress Co., Ltd.
Shelf life: >2 years if stored properly Drug formulation: This drug may be formulated in DMSO ......by MedKoo Biosciences, Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000014037

Storage condition

Storage condition:Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). Stock solution storage:0 - 4 C for short term (days to weeks), or -20 C for long term (months). Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. by MedKoo Biosciences, Inc.

Solubility

Soluble in DMSO, not in water by MedKoo Biosciences, Inc.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
BGB-102 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen Pharmaceutica N.V., Belgium Protein Kinase Inhibitors|Antineoplastic Protocols|Clinical Trial, Phase 1|Maximum Tolerated Dose|Pharmacokinetics|Advanced Malignancies|Solid Malignancies 2006/8/1 Phase 1
7

Safety Data of BGB-102

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
BOC Sciences
CHEMSCENE, LLC 1mg/USD1536();5mg/USD3072() USA
MedChemexpress Co., Ltd. 1mg/USD1536();5mg/USD3072() USA
MedKoo Biosciences, Inc. USA
Shanghai Haoyuan Chemexpress Co., Ltd. 1mg/USD1536();5mg/USD3072() China
10

Related Products

Other Forms of 807640-87-5

Name CAS No Formula MW

Recommended Compounds in EGFR

Name CAS No Formula MW
Ginsenoside Rh2 78214-33-2 C36H62O8 622.87
Mutated EGFR-IN-1 1421372-66-8 C25H31N7O 445.56
AZD-9291 (mesylate) 1421373-66-1 C29H37N7O5S 595.71
Mutant EGFR inhibitor 1421373-62-7 C27H30ClN7O2 520.03
AZD-9291 1421373-65-0 C28H33N7O2 499.61
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
WHI-P180 211555-08-7 C16H15N3O3 297.31
Gefitinib (hydrochloride) 184475-55-6 C22H25Cl2FN4O3 483.36
Erlotinib (mesylate) 248594-19-6 C23H27N3O7S 489.54
Poziotinib 1092364-38-9 C23H21Cl2FN4O3 491.34
CO-1686 (hydrobromide) 1446700-26-0 C27H29BrF3N7O3 636.46
CO-1686 1374640-70-6 C27H28F3N7O3 555.55
CNX-2006 1375465-09-0 C26H27F4N7O2 545.53
PD168393 194423-15-9 C17H13BrN4O 369.2153
AG 18 118409-57-7 C10H6N2O2 186.17
Afatinib (dimaleate) 850140-73-7 C32H33ClFN5O11 718.08
Chrysophanol 481-74-3 C15H10O4 254.2375
AG-1478 153436-53-4 C16H14ClN3O2 315.75
Mubritinib 366017-09-6 C25H23F3N4O2 468.47
AST-1306 (TsOH) 1050500-29-2 C31H26ClFN4O5S 621.08

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

Protocol Reference

13

More Information

BGB-102

Tags: buy 807640-87-5 IC50 | 807640-87-5 price | 807640-87-5 cost | 807640-87-5 solubility | 807640-87-5 purchase | 807640-87-5 manufacturer | 807640-87-5 research buy | 807640-87-5 order | 807640-87-5 MSDS | 807640-87-5 chemical structure | 807640-87-5 Storage condition | 807640-87-5 molecular weight | 807640-87-5 mw | 807640-87-5 datasheet | 807640-87-5 supplier | 807640-87-5 cell line | 807640-87-5 NMR | 807640-87-5 MS | 807640-87-5 IR | 807640-87-5 solubility | 807640-87-5 Safe information | 807640-87-5 Qc and Spectral Information | 807640-87-5 Clinical Information | 807640-87-5 Clinical Trial | 807640-87-5 Route of Synthesis | 807640-87-5 storage condition | 807640-87-5 diseases and conditions | 807640-87-5 flash point | 807640-87-5 boiling point | 807640-87-5 melting point | 807640-87-5 storage condition | 807640-87-5 brand